Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches by Aravind Sanjeevaiah, Haeseong Park, Benjamin Fangman, Matthew Porembka

Get full text

Screening of Carbofuran-Degrading Bacteria <i>Chryseobacterium</i> sp. BSC2-3 and Unveiling the Change in Metabolome during Carbofuran Degradation by Haeseong Park, Sun Il Seo, Ji-Hwan Lim, Jaekyeong Song, Joo-Hyun Seo, Pyoung Il Kim

Get full text

A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinoma by Gregory Vlacich, Andrew Ballard, Shahed N. Badiyan, Matthew Spraker, Lauren Henke, Hyun Kim, A. Craig Lockhart, Haeseong Park, Rama Suresh, Yi Huang, Cliff G. Robinson, Jeffrey D. Bradley, Pamela P. Samson

Get full text

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer by Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers-Lenz, Hui Tian, Wenyuan Xiong, Remigiusz Kaleta, Razelle Kurzrock

Get full text

Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development by Neeltje Steeghs, Aaron R. Hansen, Glenn J. Hanna, Elena Garralda, Haeseong Park, James Strauss, Michael Adam, Gossett Campbell, Jennifer Carver, Rachael Easton, Katherine Mays, Peter Skrdla, Herbert Struemper, Michael L. Washburn, Christopher Matheny, Sarina A. Piha‐Paul

Get full text

Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting. by Francesca Fontana, Alison K Esser, Christopher Egbulefu, Partha Karmakar, Xinming Su, John S Allen, Yalin Xu, Jennifer L Davis, Ariel Gabay, Jingyu Xiang, Kristin A Kwakwa, Brad Manion, Suzanne Bakewell, Shunqiang Li, Haeseong Park, Gregory M Lanza, Samuel Achilefu, Katherine N Weilbaecher

Get full text

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers by James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa

Get full text

716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or ga... by Jean-Yves Blay, Antoine Italiano, Stephane Champiat, Paolo Antonio Ascierto, Manish Sharma, Jeeyun Lee, Luis Paz-Ares Rodriguez, Keun-Wook Lee, Yoon-Koo Kang, Drew Rasco, Edith A Perez, Mariano Ponz-Sarvise, Lu Xu, Jean-Philippe Spano, Coya Tapia, Ecaterina Dumbrava, Kathleen Moore, Jason Ptacek, Michele Magni, Alfonso Cortes Salgado, Ming Yin, Agnese Losurdo, Antoine Deleuze, Mark D Pegram, Ardaman Shergill, Alexander I Spira, Michael N Alonso, Joan Albanell Mestres, Marta GilMartin, Arielle Heeke, Ana Oaknin Benzaquen, Ignacio Ortego Zabalza, Haeseong Park, Cecile Vicier, Ivan Victoria, Benjamin Weinberg, Bob T Li